Proliferating cell nuclear antigen (PCNA) immunoreactivity in stage I endometrial carcinoma: A new prognostic factor

International Journal of Gynecological Cancer

Volumn 6, Issue 3, 1996, Pages 186-192

  Garzetti, G G ^a   Ciavattini, A ^a   Goteri, G ^a   Stramazzotti, D ^a   Fabris, G ^a   Mannello, B ^a   Romanini, C ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Disease free survival; Endometrial carcinoma; Immunoreactivity; PCNA index; Prognosis; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030000416     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06030186.x     Document Type: Article

References (29)

1. Parazzini F, La Vecchia C, Bocciolone E, Franchini S. The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41: 1-16.
2. Di Saia PJ, Creasman T. Clinical Gynecologic Oncology. 3rd edn. St Louis, Washington DC, Toronto: The CV Mosby Company, 1989; 161-97.
3. Gusberg SB. Virulence factors in endometrial cancer. Cancer 1993; 71: 1464-6.
4. Vavra N, Denison U, Kucera H, et al. Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gynecol Scand 1993; 72: 205-9.
5. Podczaski E, Kaminski P, Gurski K, et al. Detection of patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 1992; 47: 323-7.
6. Rotman M, Aziz H, Halpern J, Schwartz D, Sohn C, Choi K. Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer 1993; 71: 1471-9.
7. International Federation of Gynecological and Obstetrics (FIGO). Annual Report on the Results of Treatment in Gynecological Cancer. Stockholm: FIGO, 1988, vol 18.
8. Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups. Cancer 1988; 61: 538-45.
9. Sorbe B, Risbera B, Frankendal B. DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 1990; 38: 22-7.
10. Newbury R, Scherch C, Goodspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 1990; 76: 251-7.
11. Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC. Flow cytometric analysis of stage I endometrial carcinoma. Gynecol Oncol 1989; 34: 317-22.
12. Rosemberg P, Wingren S, Simonsen E, Stal O, Risberg B, Nordenskjold B. Flow cytometric measurements of DNA index and S-phase on paraffin embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol 1989; 35: 50-4.
13. Lindahl B, Ranstam J, Wilen R. Five year survival rate in endometrial carcinoma stages I-II: influence of degree of tumour differentiation, age, myometrial invasion and DNA content. Br J Obstet Gynaecol 1994; 101: 621-5.
14. Charpin C, Andrac L, Habib MC, et al. Immunocytochemical assays in human endometrial carcinomas: a multiparametric computerized analysis and comparison with nonmalignant changes. Gynecol Oncol 1989; 33: 9-22.
15. Yu CCW, Hall PA, Fletcher CDM, et al. Haemangiopericytomas: the prognostic value of immunohistochemical staging with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology 1991; 19: 29-33.
16. Oka K, Hoshi T, Arai T. Prognostic significance of the PC 10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer 1992; 70: 1545-50.
17. Onsrud M, Kolstad P, Normann T. Postoperative external pelvic irradiation in carcinoma of the corpus uteri stage I: a controlled clinical trial. Gynecol Oncol 1976; 4: 222-31.
18. Poulsen HE, Taylor SW, Sobin LH. Histological Typing of Female Genital Tract Tumours. International Histological Classification of Tumours. Geneva: World Health Organization 1975; 13: 64-5.
19. FIGO stage-1988 revision [Announcements]. Gynecol Oncol 1989; 35: 125-7.
20. Hsu SM, Raine L, Fanoer H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981; 29: 577-80.
21. Sternberger LA. Immunohistochemistry. 2nd edn. New York, Chichester, Brisbane, Toronto: John Wiley & Sons, 1979.
22. Mittal KR, Demopoulos RI, Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am J Surg Pathol 1993; 17: 117-22.
23. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Scwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptors content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990; 94: 247-54.
24. Runowicz CD, Nuctern LM, Braunstein JD, Jones JG. Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol Oncol 1990; 38: 437-41.
25. Garzetti GG, Ciavattini A, Goteri G, et al. Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol 1994; 55: 111-4.
26. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115-24.
27. Battersby S, Anderson T. Correlation using PCNA/cyclin. Human Pathol 1990; 21: 781 (letter).
28. Pelosi G, Zamboni G, Doglioni C, et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol 1992; 16: 1215-25.
29. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-9.